This article summarized the latest R&D progress of Rivastigmine Tartrate, the Mechanism of Action for Rivastigmine Tartrate, and the drug target R&D trends for Rivastigmine Tartrate.

On October 20, 2023, “Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts) ”was reported at the ESMO Congress.

Amgen has revealed fresh information from the Phase 2 trial of dazodalibep, an experimental drug aimed to treat Sjögren's.

BRAF mutation is one of the significant therapeutic targets for various solid tumors, with BRAF inhibitors representing a major form of targeted combination therapy for BRAF mutation-positive solid tumors.

This article summarized the latest R&D progress of Sacituzumab govitecan-hziy, the Mechanism of Action for Sacituzumab govitecan-hziy, and the drug target R&D trends for Sacituzumab govitecan-hziy.

[177Lu]Lu-PSMA-617 extends survival in mCRPC patients previously treated with ARPI, but its impact without prior taxane treatment was unclear until revealed at the ESCO Congress.

FluoGuide A/S, a precision oncology surgery leader, shared initial results from the phase IIa trial of its leading product, FG001, for head and neck cancer surgeries, at the International Academy of Oral Oncology 2023 conference in South Korea. The study validated the product's efficacy and safety.

β-Inhibitors can inhibit the activity of β-lactamase inhibitors produced by drug-resistant bacteria. They are typically used in combination with β-lactam antibiotics to protect the β-lactam antibiotics from hydrolysis, thereby inhibiting enzyme-resistant bacteria.

This article summarized the latest R&D progress of Pilocarpine Hydrochloride, the mechanism of action for Pilocarpine Hydrochloride, and the drug target R&D trends for Pilocarpine Hydrochloride.

New data from the 2023 ASH conference is now available on the Clinical Results section of the Synapse database.

MoonLake Immunotherapeutics, a clinical-stage biotech firm, announced encouraging preliminary results from its global Phase 2 ARGO trial. This trial evaluated the efficacy and safety of Nanobody® sonelokimab in patients with active psoriatic arthritis.

The overexpression of BCL-2 protein allows tumor cells to evade apoptosis and to become resistant to a variety of anti-tumor drugs. Bcl-2 inhibitors are a new type of anti-cancer drug developed to target the mechanism of apoptosis, promoting cell death.